Diary

  • Tue
    26
    Jun
    2018

    Royal Marsden Hospital

    Description: Using a combination of colourful diagrams and clear explanations, I will describe the gene mutations and other defects that drive ovarian cancer (including fallopian tube and other primary peritoneal cancers). I will also examine how this knowledge impacts treatment choice and explain the science behind chemotherapy and PARP, B-Raf and angiogenesis inhibitors. The day will also include the potential of immunotherapy and novel approaches for treatment, screening and patient monitoring.
    Level: Intermediate
    Audience: Ideal for anyone with an A level or equivalent understanding of cell biology and genetics and who works with cancer patients, data or treatments.
    Cost: TBC
    To book, contact: conferenceteam@rmh.nhs.uk or call: 020 7808 2922
    View an outline of the programme

     

  • Wed
    11
    Jul
    2018

    Royal Marsden Hospital, London

    Description: In this study day I describe the unique cellular and genetic features of haematological cancers and covers a diverse range of targeted treatments for leukaemias, lymphomas and multiple myeloma. Treatments explained include a wide range of monoclonal antibodies, B cell receptor signalling blockers and JAK2, Bcl-2, FLT3 and CDK inhibitors. I also explore the potential of immunotherapy with checkpoint inhibitors and CAR T cells.
    Level: Intermediate/Advanced
    Audience:Ideal for pharmacists, research nurses, people from pharmaceutical companies, junior doctors or anyone who has been on one of my other courses. Requires a basic understanding of cancer genetics and cancer cell biology.
    Cost: TBC
    To book, contact: conferenceteam@rmh.nhs.uk or call: 020 7808 2922
    View an outline of the programme